Mackay Shields LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 17.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 880,844 shares of the biopharmaceutical company’s stock after selling 185,815 shares during the quarter. Mackay Shields LLC’s holdings in Pfizer were worth $34,493,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of PFE. Vanguard Group Inc. raised its holdings in Pfizer by 1.2% in the second quarter. Vanguard Group Inc. now owns 456,203,630 shares of the biopharmaceutical company’s stock valued at $17,864,934,000 after acquiring an additional 5,289,511 shares in the last quarter. BlackRock Inc. raised its holdings in Pfizer by 0.3% in the second quarter. BlackRock Inc. now owns 407,048,272 shares of the biopharmaceutical company’s stock valued at $15,940,011,000 after acquiring an additional 1,314,302 shares in the last quarter. Geode Capital Management LLC raised its holdings in Pfizer by 2.4% in the second quarter. Geode Capital Management LLC now owns 96,381,189 shares of the biopharmaceutical company’s stock valued at $3,764,312,000 after acquiring an additional 2,233,072 shares in the last quarter. Legal & General Group Plc raised its holdings in Pfizer by 4.0% in the second quarter. Legal & General Group Plc now owns 37,393,513 shares of the biopharmaceutical company’s stock valued at $1,464,331,000 after acquiring an additional 1,434,331 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Pfizer by 34.5% in the second quarter. Franklin Resources Inc. now owns 35,709,729 shares of the biopharmaceutical company’s stock valued at $1,398,393,000 after acquiring an additional 9,156,521 shares in the last quarter. 64.93% of the stock is currently owned by institutional investors and hedge funds.
Shares of PFE stock traded up $0.40 during midday trading on Thursday, reaching $41.82. 376,067 shares of the company traded hands, compared to its average volume of 30,215,465. The firm’s 50 day simple moving average is $45.45 and its two-hundred day simple moving average is $41.51. Pfizer Inc. has a 1-year low of $33.36 and a 1-year high of $51.86. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12. The firm has a market cap of $234.47 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Stockholders of record on Friday, November 5th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, November 4th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is 70.27%.
In other Pfizer news, SVP Jennifer B. Damico sold 1,661 shares of Pfizer stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $48.30, for a total value of $80,226.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the sale, the senior vice president now directly owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Several equities research analysts recently commented on the stock. Mizuho reiterated a “hold” rating and set a $43.00 price target on shares of Pfizer in a research note on Sunday, October 3rd. The Goldman Sachs Group set a $48.00 price objective on Pfizer in a report on Thursday, July 29th. Truist assumed coverage on Pfizer in a report on Tuesday, July 27th. They set a “buy” rating and a $43.00 price objective on the stock. SVB Leerink increased their target price on shares of Pfizer from $49.00 to $50.00 and gave the stock a “market perform” rating in a research note on Monday, September 20th. Finally, Royal Bank of Canada set a $44.00 price objective on shares of Pfizer in a research report on Thursday, July 29th. Ten research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $43.42.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Further Reading: How to Trade Using Analysts Ratings
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.